Literature DB >> 18213512

Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity.

S Ashraf Ahmed1, Mark A Olson, Matthew L Ludivico, Janice Gilsdorf, Leonard A Smith.   

Abstract

Type A botulinum neurotoxin is one of the most lethal of the seven serotypes and is increasingly used as a therapeutic agent in neuromuscular dysfunctions. Its toxic function is related to zinc-endopeptidase activity of the N-terminal light chain (LC) on synaptosome-associated protein-25 kDa (SNAP-25) of the SNARE complex. To understand the determinants of substrate specificity and assist the development of strategies for effective inhibitors, we used site-directed mutagenesis to investigate the effects of 13 polar residues of the LC on substrate binding and catalysis. Selection of the residues for mutation was based on a computational analysis of the three-dimensional structure of the LC modeled with a 17-residue substrate fragment of SNAP-25. Steady-state kinetic parameters for proteolysis of the substrate fragment were determined for a set of 16 single mutants. Of the mutated residues non-conserved among the serotypes, replacement of Arg-230 and Asp-369 by polar or apolar residues resulted in drastic lowering of the catalytic rate constant (k(ca)), but had less effect on substrate affinity (K(m)). Substitution of Arg-230 with Lys decreased the catalytic efficiency (k(cat)/K(m)) by 50-fold, whereas replacement by Leu yielded an inactive protein. Removal of the electrostatic charge at Asp-369 by mutation to Asn resulted in 140-fold decrease in k(cat)/K(m). Replacement of other variable residues surrounding the catalytic cleft (Glu-54, Glu-63, Asn-66, Asp-130, Asn-161, Glu-163, Glu-170, Glu-256), had only marginal effect on decreasing the catalytic efficiency, but unexpectedly the substitution of Lys-165 with Leu resulted in fourfold increase in k(cat)/K(m). For comparison purposes, two conserved residues Arg-362 and Tyr-365 were investigated with substitutions of Leu and Phe, respectively, and their catalytic efficiency decreased 140- and 10-fold, respectively, whereas substitution of the tyrosine ring with Asn abolished activity. The altered catalytic efficiencies of the mutants were not due to any significant changes in secondary or tertiary structures, or in zinc content and thermal stability. We suggest that, despite the large minimal substrate size for catalysis, only a few non-conserved residues surrounding the active site are important to render the LC competent for catalysis or provide conformational selection of the substrate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213512     DOI: 10.1007/s10930-007-9118-8

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  40 in total

Review 1.  Other noncosmetic uses of BOTOX.

Authors:  J Verheyden; A Blitzer; M F Brin
Journal:  Semin Cutan Med Surg       Date:  2001-06

2.  Free-energy contributions to complex formation between botulinum neurotoxin type B and synaptobrevin fragment.

Authors:  Mark A Olson; Timothy L Armendinger
Journal:  Protein Eng       Date:  2002-09

3.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

4.  Crystal structure of botulinum neurotoxin type A and implications for toxicity.

Authors:  D B Lacy; W Tepp; A C Cohen; B R DasGupta; R C Stevens
Journal:  Nat Struct Biol       Date:  1998-10

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release.

Authors:  R A Steinhardt; G Bi; J M Alderton
Journal:  Science       Date:  1994-01-21       Impact factor: 47.728

7.  Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active.

Authors:  S A Ahmed; L A Smith
Journal:  J Protein Chem       Date:  2000-08

8.  Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain.

Authors:  L Li; T Binz; H Niemann; B R Singh
Journal:  Biochemistry       Date:  2000-03-07       Impact factor: 3.162

9.  The beta subunit of tryptophan synthase. Clarification of the roles of histidine 86, lysine 87, arginine 148, cysteine 170, and cysteine 230.

Authors:  E W Miles; H Kawasaki; S A Ahmed; H Morita; H Morita; S Nagata
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

10.  Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.

Authors:  Nicholas R Silvaggi; Grant E Boldt; Mark S Hixon; Jack P Kennedy; Saul Tzipori; Kim D Janda; Karen N Allen
Journal:  Chem Biol       Date:  2007-05
View more
  16 in total

1.  Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.

Authors:  Xin Hu; Patricia M Legler; Noel Southall; David J Maloney; Anton Simeonov; Ajit Jadhav
Journal:  J Comput Aided Mol Des       Date:  2014-06-24       Impact factor: 3.686

Review 2.  Toxins from bacteria.

Authors:  James S Henkel; Michael R Baldwin; Joseph T Barbieri
Journal:  EXS       Date:  2010

3.  Systematic discovery of molecular probes targeting multiple non-orthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A).

Authors:  Saedeh Dadgar; Wely B Floriano
Journal:  Mol Cell Probes       Date:  2015-03-04       Impact factor: 2.365

4.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

5.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

6.  Structural framework for covalent inhibition of Clostridium botulinum neurotoxin A by targeting Cys165.

Authors:  Enrico A Stura; Laura Le Roux; Karine Guitot; Sandra Garcia; Sarah Bregant; Fabrice Beau; Laura Vera; Guillaume Collet; Denis Ptchelkine; Huseyin Bakirci; Vincent Dive
Journal:  J Biol Chem       Date:  2012-08-06       Impact factor: 5.157

7.  Catalytic properties of botulinum neurotoxin subtypes A3 and A4.

Authors:  James S Henkel; Mark Jacobson; William Tepp; Christina Pier; Eric A Johnson; Joseph T Barbieri
Journal:  Biochemistry       Date:  2009-03-24       Impact factor: 3.162

Review 8.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

Review 9.  Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering.

Authors:  Thomas Binz; Stefan Sikorra; Stefan Mahrhold
Journal:  Toxins (Basel)       Date:  2010-04-13       Impact factor: 4.546

Review 10.  Towards new uses of botulinum toxin as a novel therapeutic tool.

Authors:  Andy Pickett; Karen Perrow
Journal:  Toxins (Basel)       Date:  2011-01-12       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.